Let’s talk crypto, Metaverse, NFTs, CeDeFi, and Stocks, and focus on multi-chain as the future of blockchain technology.
Let us all WIN!
Dogecoin Takes The Lead as Oprah Winfrey and Dwayne Johnson … cryptonewsbytes.com
Source link ]]>
The pharmaceutical segment reported the highest sales with about $13.71 billion, followed by MedTech with a total sales of about $7.78 billion, and the remaining accrued from the consumer health segment.
One of the oldest American pharmaceutical and consumer packaged goods companies, Johnson & Johnson (NYSE: JNJ) announced its second quarter (Q2) 2023 earnings on July 20, which ostensibly beat Wall Street expectations. According to the company’s announcement, the second quarter sales grew by about 6.3 percent and the operational growth excluding the COVID-19 vaccine jumped by 8.9 percent. Meanwhile, the company’s Joaquin Duato, Chairman of the Board and Chief Executive Officer highlighted that the future is bright for its vast products, especially as it moves ahead to split its shares.
“We are entering the back half of the year from a position of strength with numerous catalysts, including becoming a two-sector company focused on Pharmaceutical and MedTech innovation,” Duato noted.
Johnson & Johnson Q2 2023 Financial Highlights
During the second quarter of 2023, the company announced adjusted earnings per share of $2.80 compared to $2.62 expected by analysts surveyed by Refinitiv. Additionally, Johnson & Johnson announced revenue of about $25.53 billion compared to the $24.62 billion expected by analysts surveyed by Refinitiv. Splitting the sales, the company announced that it collected about $13.44 billion from the United States market and the remaining $22 billion from the international market.
The pharmaceutical segment reported the highest sales with about $13.71 billion, followed by MedTech with a total sales of about $7.78 billion, and the remaining accrued from the consumer health segment. Although the company is facing several headwinds including some legal proceedings, it highlighted that the coming quarters could as well be profitable as the prior one.
As a result, the company announced that it will be increasing its 2023 full-year guidance midpoints for adjusted operational sales excluding the COVID-19 vaccine and the adjusted operating earnings per share. Notably, the company is forecasting its full-year sales to come in between $98.80 billion to $99.80 billion, which is about $1 billion higher than the guidance issued in April. Additionally, the company’s full-year earnings outlook is expected to come in between $10.70 to $10.80 per share, which is higher than the prior one issued in April between $10.60 to $10.70 per share.
Amid the legal litigations most centered on allegations that its pharmaceutical products are causing cancer to its users, the company has focused on splitting its pharma segment and MedTech segment for future growth prospects.
Market Outlook
The $413 billion valued company has been on the receiving end in the past two years. According to the latest stock market data, JNJ shares have dropped approximately 7.3 percent and 10 percent in the last year and YTD respectively. Nonetheless, 21 analysts are still optimistic about the company’s future performance having given the JNJ market an average rating of Over.
Despite the success of Kenvue’s IPO, Johnson & Johnson remains under allegations that some of its talc products are cancerous.
Kenvue, the consumer-health spinoff announced by Johnson & Johnson (NYSE: JNJ) last year, has become the largest US IPO in over a year after going public on Thursday. The Kenvue brand debuted on the New York Stock Exchange (NYSE), causing J&J’s shares to soar 22% on the same day. At the initial public offering (IPO), Kenvue was priced at $22 a night before its launch. However, the new company’s shares opened at $25.53 and closed at $26.90.
Kenvue Become Largest US IPO in Over a Year
Kenvue sold over 172.8 million shares during its IPO, more than the initial plan of 151 million. It secured approximately $3.8 billion from the sale, pushing the company’s valuation to approximately $41 billion. Following the public launch, Kenvue now trades under the ticker “KVUE” and covers a wide range of top consumer brands like Neutrogena, J&J’s namesake baby powder, Band-Aid, Listerine, Tylenol, and Aveeno.
Speaking on Thursday morning ahead of the debut, Kenvue CEO Thibaut Mongon was confident that millions globally woke up with at least one of the company’s products in their homes. Mongon used to be J&J’s executive vice president and worldwide chair of consumer health. Now, he will serve on Kenvue’s board.
Interestingly, Kenvue has been stacking up profits before its IPO. According to reports filed with the US Securities and Exchange Commission (SEC), the J&J subsidiary generated $14.95 billion in sales for 2022 and a net income of $1.46 billion on a pro forma basis.
Additionally, first-quarter sales were around $3.85 billion, while its net income was about $330 million. It considers these results preliminary as it aims to grow its global annual sales through 2025 by 3-4%.
Despite the success of Kenvue’s IPO, Johnson & Johnson remains under allegations that some of its talc products are cancerous. These products are registered under J & J’s newly created business, Kenvue. However, the IPO filing shows that the spinoff will only respond to talc-related liabilities outside the US and Canada.
After being questioned on the liabilities, Mongon said Kenvue is “laser-focused on what we do best: serving our customers and also our portfolio with the brands that we mentioned”.
Kenvue Rejuvenate Hope in Collapsing Market
The debut of Kenvue has raised hope for the revival of the US IPO market after it collapsed last year. According to Renaissance Capital, the company’s public debut is currently the highest IPO this year. The combined value of the 40 IPOs in 2023 is about $2.4 billion, trailing by over $1 billion compared to Kenvue.
Since 2021, no IPO has surpassed the debut of Rivian, an electric vehicle maker that went public in November 2021. Shares of Rivian (RIVN) spiked by over 50 %, from $78 per price to $106.75. Regardless, Kenvue has overtaken Rivian to become the largest IPO.
Ibukun is a crypto/finance writer interested in passing relevant information, using non-complex words to reach all kinds of audience.
Apart from writing, she likes to see movies, cook, and explore restaurants in the city of Lagos, where she resides.
Subscribe to our telegram channel.
Join
Pharmaceutical powerhouse J&J expects to price its Kenvue IPO shares at $20 to $23 for a potential $40 billion company valuation.
Johnson & Johnson (NYSE: JNJ) plans to price shares of its upcoming Kenvue Inc IPO between $20 and $23. The initial public offering roadshow constitutes more than $151 million shares of common stock and would be valued at $40 billion in the share range.
Johnson & Johnson announced it would launch the Kenvue IPO later this year in what could be the largest of its kind in the US this year. Kenvue, a wholly owned subsidiary of the pharmaceutical giant that comprises its Consumer Health Business, expects to grant the underwriters additional share purchase options. The J&J spinoff would allow a 30-day option to purchase 22,680,600 more shares of common stock. Commentaries explain that this other stock would cover any possible over-allotments during the IPO’s initial launch.
J&J, which reportedly met with prospective investors on Monday, will own 1,716,160,000 shares of Kenvue’s common stock. This stake represents almost 92% of the total outstanding shares of the health spinoff’s common stock. However, J&J’s Kenvue stake could also end up being just under 91% if the underwriters fully exercise their over-allotment option.
Kenvue IPO Eyes $3.15M in Net Proceeds
In a regulatory filing Monday, Johnson & Johnson estimated that the Kenvue IPO would realize approximately $3.15 million in net proceeds. The New Jersey-based pharmaceutical giant also stated that it would claim all proceeds and profits from related debt-financing transactions. J&J did not specify when it expects to complete its separation from Kenvue. However, the company said it would likely happen by mid to late 2023, with Kenvue trading on the New York Stock Exchange as KVUE.
In a preliminary prospectus filed with the Securities and Exchange Commission (SEC), J&J listed the IPO’s lead underwriters. The pharmaceutical corporation said Goldman Sachs (NYSE: GS), JPMorgan (NYSE: JPM), and Bank of America (NYSE: BAC) are the joint lead book-running managers for the IPO.
Johnson & Johnson’s Consumer Health Business sells products ranging from Band-Aid bandages and Listerine mouthwash to pain reliever Tylenol and Johnson’s baby powder. In addition, the consumer healthcare and medical technology corporation also produces and sells skin care products like Neutrogena and Aveeno.
J&J Consumer Health Business
In 2022, J&J’s Consumer Health Business generated $15 billion in net revenue and $3.8 billion in sales in Q1 2023. According to J&J’s latest earnings report, the unit’s last quarter haul is a more than 7% increase compared to the previous year. Although the pharmaceutical giant beat earnings and revenue expectations for the year’s first quarter, it lowered its pharmaceutical sales guidance.
Johnson & Johnson pulled in $24.75 billion in revenue for the period that ended March 31st. The company’s revenue is higher than the $23.67 billion analysts expected. Commenting on the quarterly performance, the company’s Chairman of the Board and Chief Executive Officer Joaquin Duato said:
“Our first quarter results demonstrate strong performance across all three segments of our business and reflect the dedication of Johnson & Johnson colleagues around the world. With this momentum, I look forward to the remainder of the year, one filled with exciting catalysts that will create both near- and long-term value for patients and all of our stakeholders.”
For Q1 2023, J&J also realized earnings per share (EPS) of $2.68 adjusted versus the $2.50 consensus estimate.
Tolu is a cryptocurrency and blockchain enthusiast based in Lagos. He likes to demystify crypto stories to the bare basics so that anyone anywhere can understand without too much background knowledge.
When he’s not neck-deep in crypto stories, Tolu enjoys music, loves to sing and is an avid movie lover.
Subscribe to our telegram channel.
Join